NY-BLACKROCK
BlackRock Inc. (NYSE: BLK) today announced a minority investment in Clarity AI, a sustainability analytics and data science platform, as the firm continues to invest in delivering sustainable investing analytics and software for clients. BlackRock will integrate Clarity AI’s capabilities with Aladdin®, BlackRock’s end-to-end operating system for investment professionals.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210114005634/en/
Clarity AI uses big data and machine learning to create actionable sustainability and impact insights and expand these to a uniquely broad universe of companies, countries and local governments. Its proprietary technology and data science capabilities across environmental and social impact analyze more than 30,000 companies, spanning almost 200 countries. Clarity AI also supports regulatory and client reporting to help investors meet new sustainability disclosure obligations.
“Investors are galvanized around sustainability as a critical consideration in managing immediate and future risks, and better data is foundational to this,” said Mary-Catherine Lader, Head of Aladdin Sustainability at BlackRock . “As BlackRock makes sustainability its standard for investing, we are committed to raising the standards for ESG data and technology. We’re investing in new analytics and software in Aladdin and are also integrating capabilities from strategic partners like Clarity AI so clients can understand their investments’ social and environmental impact and risks. Clarity AI’s capabilities use machine learning to help Aladdin clients analyze a broader universe of companies, address their disclosure obligations and build more sustainable portfolios.”
“BlackRock’s investment in Clarity AI and the integration of our capabilities and comprehensive ESG, sustainability and impact data into BlackRock’s Aladdin platform will be transformative, bringing Clarity AI data and analytics to more of the world’s largest and most significant investors,” said Rebeca Minguela, Founder and CEO of Clarity AI . “This strategic partnership with BlackRock reflects the growing demand for our innovative approach in helping investors assess the impact of companies on our society and planet.”
Demand for sustainable investing accelerated rapidly in 2020. Global investors in mutual funds and ETFs invested $326 billion in sustainable assets in the 12 months to November 2020, a 97% increase over the same period in the prior year1 . In addition, a recent survey2 of global investors shows that their allocations to ESG strategies are expected to double by 2025. Within the survey2 , 53% of respondents cited concerns about “poor quality or availability of ESG data and analytics” as their biggest barrier to adopting sustainable investing. As more investors look for ways to evaluate the social and environmental impact of their investments, the need for improved ESG data and analytics in individual investments and across whole portfolios will continue to grow.
Clarity AI builds on the existing sustainability dataset in the Aladdin platform with additional forward-looking sustainability analytics and models, generated from data about companies. These insights complement traditional corporate ESG disclosures.
This investment is the latest step from BlackRock’s Aladdin platform as it continues to invest in its sustainability capabilities, which last year added 1,200 sustainability metrics and established data partnerships to help investors understand ESG and physical climate risks and opportunities.
BlackRock also recently unveiled Aladdin Climate, which helps investors understand and act on climate risk. It is the first software application to offer investors measures of both the physical risk of climate change and the transition risk to a low-carbon economy on portfolios.
BlackRock will join existing investors including Deutsche Börse, Kibo Ventures, Mundi Ventures, Seaya Ventures and Founders Fund.
The terms of the transaction were not disclosed.
About BlackRock
BlackRock’s purpose is to help more and more people experience financial well-being. As a fiduciary to investors and a leading provider of financial technology, we help millions of people build savings that serve them throughout their lives by making investing easier and more affordable. For additional information on BlackRock, please visit www.blackrock.com/corporate .
About Aladdin
Aladdin® is BlackRock’s end-to-end investment management and operations platform used by institutional investors including asset managers, pension funds, insurers and corporate treasurers. It combines sophisticated risk analytics with comprehensive portfolio management, trading and operations tools on a single, unified platform. Also customized for wealth managers, the Aladdin platform provides a common language across the investment lifecycle and enables a culture of risk transparency among users.
About Clarity AI
Clarity AI is a global data science and technology platform that uses machine learning and big data to deliver environmental and social data that empowers investors to measure the impact of their portfolios. Clarity AI’s platform analyzes more than 30,000 companies, 200,000 funds and 400 countries and local governments, delivering data, analytics and software applications for investment and corporate research and reporting. Founded in 2017, Clarity AI has offices in the US, UK and Spain and a client network with over $10 trillion assets under management. Clarity AI’s team is specialized in technology, sustainability and research, with collective experience from leading organizations, businesses and research institutions including NASA, the World Bank, Google, McKinsey & Company, Morgan Stanley, J.P. Morgan, Harvard, M.I.T and more. For additional information on Clarity AI, please visit www.clarity.ai .
___________________
1
Simfund, Broadridge, GBI. Data as of Nov 2020. Closed-end funds, FoFs excluded; Money Market funds included.
2
BlackRock 2020 Global Sustainable Investing Survey, which includes responses from 425 clients in 27 countries representing an estimated $25 trillion in assets under management: https://www.blackrock.com/corporate/literature/publication/blackrock-sustainability-survey.pdf
View source version on businesswire.com: https://www.businesswire.com/news/home/20210114005634/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom